{"id":10071,"date":"2024-07-25T14:30:00","date_gmt":"2024-07-25T06:30:00","guid":{"rendered":"https:\/\/credevo.com\/articles\/?p=10071"},"modified":"2025-06-21T13:50:01","modified_gmt":"2025-06-21T05:50:01","slug":"why-asia-pacific-is-becoming-a-hub-for-bioavailability-ba-bioequivalence-be-studies","status":"publish","type":"post","link":"https:\/\/credevo.com\/articles\/2024\/07\/25\/why-asia-pacific-is-becoming-a-hub-for-bioavailability-ba-bioequivalence-be-studies\/","title":{"rendered":"Why Asia-Pacific Is Becoming A Hub For Bioavailability (BA) & Bioequivalence (BE) Studies?"},"content":{"rendered":"\n

Bioavailability and bioequivalence (BA\/BE) studies in the Asia-Pacific region are gaining significant momentum. The rising cost of medicines worldwide is driving a strong demand for more affordable healthcare options. In this context, the generic drug market is emerging as a promising alternative, offering consumers access to medications at more reasonable prices.<\/p>\n\n\n\n

\"Asia-Pacific<\/figure>\n\n\n\n

To bring generic drugs to market, pharmaceutical companies, healthcare professionals, and regulatory bodies work closely together to ensure the safe and affordable development of these medications. BA\/BE studies are crucial in achieving this goal, and the Asia-Pacific region offers a time- and cost-efficient environment for conducting these studies.<\/p>\n\n\n\n

Pharmaceutical and biotech companies are increasingly interested in exploring and expanding drug development solutions within the Asia-Pacific region.<\/p>\n\n\n\n

To better understand this trend, it is important to clarify the meaning of key acronyms like BA\/BE and their critical role in the drug development process.<\/p>\n\n\n\n

What are BA\/BE studies?<\/h2>\n\n\n\n

Bioavailability (BA)<\/strong><\/h4>\n\n\n\n

Bioavailability studies are clinical investigations that measure the extent and rate at which the active ingredient or active moiety of a drug becomes available in the systemic circulation when administered in a specific dosage form. These studies are crucial for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body.<\/p>\n\n\n\n

Bioequivalence (BE)<\/strong><\/h4>\n\n\n\n

Bioequivalence studies are a type of clinical research that compares the bioavailability of a generic drug to that of a reference (brand-name) drug. The primary goal is to determine whether the generic product releases its active ingredient into the bloodstream at the same rate and extent as the original branded drug.<\/p>\n\n\n\n

Why should you choose the Asia-Pacific region for BA\/BE studies? <\/h2>\n\n\n\n

There are several compelling reasons why the Asia-Pacific region is becoming a significant hub for bioavailability and bioequivalence (BA\/BE) studies. Some key factors include:<\/p>\n\n\n\n

1. Diverse and large population base.<\/h4>\n\n\n\n

Home to approximately 60% of the world\u2019s population, offering a diverse pool for participant recruitment and a substantial workforce. This diversity and abundance help reduce trial recruitment times.<\/p>\n\n\n\n

2. Efficient issue resolution<\/h4>\n\n\n\n

The region provides ease of coordination for addressing issues both within organizations and with external stakeholders, including suppliers, regulatory authorities, and customers.<\/p>\n\n\n\n

3. Varied geographical and political landscape<\/h4>\n\n\n\n

Its varied geographical locations offer excellent connectivity and accessibility while providing political stability, which is crucial for conducting smooth clinical trials.<\/p>\n\n\n\n

4. Advanced technological integration<\/h4>\n\n\n\n

Asia-Pacific is at the forefront of developing cutting-edge technologies that are homegrown and easily integrated into the clinical research ecosystem.<\/p>\n\n\n\n

5. Cost-effective studies<\/h4>\n\n\n\n

Conducting studies in the Asia-Pacific region is generally more affordable compared to other regions, making it an attractive option for sponsors.<\/p>\n\n\n\n

6. Favorable time zone<\/h4>\n\n\n\n

The region’s favorable time zone allows for effective communication and coordination across various global research sites.<\/p>\n\n\n\n

7. Skilled healthcare professionals<\/h4>\n\n\n\n

The region boasts a trained and competent team of physicians, nurses, and clinical staff, ensuring the efficient conduct of clinical trials.<\/p>\n\n\n\n

8. Growing healthcare investments<\/h4>\n\n\n\n

Significant investments in both the private and public healthcare sectors in recent years have enhanced the capacity for medical care delivery and clinical research.<\/p>\n\n\n\n

9. Integrated healthcare facilities<\/h4>\n\n\n\n

The availability of comprehensive healthcare facilities, including outpatient, inpatient, and critical care units, enables seamless integration for BA\/BE studies.<\/p>\n\n\n\n

10. Presence of leading CROs<\/h4>\n\n\n\n

All major Contract Research Organizations (CROs) have a strong presence in the Asia-Pacific region and are active in major therapeutic areas, creating a competitive and cost-effective environment for sponsors.<\/p>\n\n\n\n

11. Streamlined approval processes<\/h4>\n\n\n\n

In many Asia-Pacific countries, approvals for Institutional Review Boards (IRBs), regulatory requirements, import licensing, and contract negotiations can often be processed simultaneously, reducing timelines.<\/p>\n\n\n\n

12. Supportive regulatory environment<\/h4>\n\n\n\n

Governments in the Asia-Pacific region are continuously working to set goals, develop strategies, and implement plans to improve the regulatory environment for BA\/BE studies.<\/p>\n\n\n\n

These factors collectively make the Asia-Pacific region an increasingly attractive destination for conducting BA\/BE studies, offering efficiency, cost savings, and access to a diverse population.<\/p>\n\n\n\n

Challenges in conducting BA\/BE studies in the Asia-Pacific region and solutions to overcome them<\/h2>\n\n\n\n

Conducting bioavailability and bioequivalence (BA\/BE) studies in the Asia-Pacific region presents several challenges. However, with strategic planning and targeted solutions, these challenges can be effectively addressed:<\/p>\n\n\n\n

1. Aging population<\/h4>\n\n\n\n

Certain areas within the Asia-Pacific region have a higher proportion of aging populations, which limits their participation in clinical studies due to eligibility and health concerns.<\/p>\n\n\n\n

Solution<\/strong>: A well-defined site selection process is critical to overcoming this issue. This involves establishing a set of criteria for evaluating potential sites for BA\/BE studies, considering factors such as location, accessibility, infrastructure, environmental considerations, and proximity to suppliers, patients, the target population, and customers. Identifying the right site ensures access to an appropriate and diverse pool of study participants.<\/p>\n\n\n\n

2. Language barriers<\/h4>\n\n\n\n

In some parts of the region, English is not widely spoken, leading to challenges in communication and a heavy reliance on native speakers for conducting studies.<\/p>\n\n\n\n

Solution<\/strong>: To address language barriers, it is essential to recruit and train local talent to understand the specific requirements and conditions of the study. This approach not only facilitates smoother research operations but also creates job opportunities for the local community, thereby building trust and fostering collaboration with local governments. Government participation is vital for obtaining approvals for various regulatory and ethical measures.<\/p>\n\n\n\n

3. Environmental factors<\/h4>\n\n\n\n

Environmental factors play a significant role in developing policies, frameworks, and products, which in turn influence costs and market dynamics. Issues such as regional variations in costs, supply chains, and resource management can affect the study’s feasibility.<\/p>\n\n\n\n

Solution<\/strong>: Leveraging technology and automation can mitigate these challenges. Diversifying suppliers, improving category-specific negotiations, and optimizing site selection can help manage supply chain complexities and enhance resource allocation efficiency.<\/p>\n\n\n\n

4. Lack of financial resources<\/h4>\n\n\n\n

Many developing countries in the Asia-Pacific region face significant financial constraints, limiting their ability to achieve health-related goals. Additionally, these countries may lack adequate technology, infrastructure, and comprehensive health policy frameworks.<\/p>\n\n\n\n

Solution<\/strong>: Financial challenges can be addressed through targeted investments in technology, infrastructure, and capacity building. Public-private partnerships, international collaborations, and funding from global health organizations can also play a pivotal role in bridging financial gaps.<\/p>\n\n\n\n

5. Delays in regulatory approvals<\/h4>\n\n\n\n

Regulatory bodies in some countries take longer to process study protocols, leading to delays in obtaining necessary approvals.<\/p>\n\n\n\n

Solution<\/strong>: Streamlining the approval process through automation and online submission of proposals can significantly reduce timelines. An optimal study design with thorough planning and strict adherence to timelines, coupled with identifying countries within the Asia-Pacific region that facilitate multicentric trials, is crucial for the commercial success of a drug. Early planning and preparation can help meet regulatory timelines and address logistical challenges in any chosen region.<\/p>\n\n\n\n

By recognizing these challenges and implementing these solutions, the Asia-Pacific region can continue to strengthen its position as a key player in the global landscape for conducting BA\/BE studies.<\/p>\n\n\n\n

Statistics behind BA\/BE studies in the Asia-Pacific region<\/h2>\n\n\n\n

1. Sponsor data<\/h4>\n\n\n\n

Over 200 pharmaceutical companies globally sponsor BA\/BE studies in the Asia-Pacific (APAC) region, a number that continues to grow each year. The APAC region is making significant strides in the global market by offering a seamless site experience, technological expertise, and robust infrastructure to manage large-scale clinical studies. The region also demonstrates study compliance levels comparable to Western standards, as indicated by the outcomes of U.S. FDA inspections.<\/p>\n\n\n\n

2. Subject data<\/h4>\n\n\n\n

In FY 2022, approximately 120,000 subjects were enrolled in BA\/BE studies across the APAC region. In the following year, the number increased to about 135,000 subjects, reflecting a 12.5% growth in enrollment. This increase underscores the significant expansion of clinical research activities in the APAC region.<\/p>\n\n\n\n

The growth can be attributed to several factors, including enhanced regulatory harmonization, increased investment in pharmaceutical research, and a stronger focus on ensuring drug safety and efficacy in the region. Additionally, digitization has enabled web-based solutions to improve trial participation, retention, and data collection, even during challenging times.<\/p>\n\n\n\n

The most active countries involved in BA\/BE studies include India<\/a>, South Korea, Thailand, Singapore, Nepal, the Philippines, Vietnam, Taiwan, and New Zealand.<\/p>\n\n\n\n

3. Trial data<\/h4>\n\n\n\n

In the first half of 2021, 3,072 clinical trials, including local and bioequivalence studies, were initiated in the APAC region. This represents a 26% increase compared to the previous year when 2,436 studies were launched.<\/p>\n\n\n\n

The largest number of BA\/BE studies initiated during this period were focused on therapeutic areas such as oncology, infectious diseases, cardiology, endocrinology, and gastroenterology. Other prominent areas included dermatology, rheumatology, and geriatrics.<\/p>\n\n\n\n

Growing therapeutic areas for conducting BA\/BE studies<\/h2>\n\n\n\n

The focus of BA\/BE studies is often aligned with trends in therapeutic areas with a high prevalence of chronic diseases. Below is a breakdown of some growing areas for BA\/BE studies:<\/p>\n\n\n\n

1. Chronic diseases<\/h4>\n\n\n\n

The demand for affordable treatment options for chronic conditions such as diabetes, cardiovascular diseases, and metabolic disorders is increasing, particularly in countries like India. This trend underscores the need for BA\/BE studies in these therapeutic areas.<\/p>\n\n\n\n

2. Oncology<\/h4>\n\n\n\n

The development of new cancer treatments is a constant priority, especially given the high number of cancer cases in the Asia-Pacific region. BA\/BE studies are crucial in demonstrating the bioequivalence of generic versions of these medications, thereby supporting the availability of more affordable treatment options.<\/p>\n\n\n\n

Number of Cancer Cases in the Asia-Pacific Region in 2022, by Country<\/strong>:<\/p>\n\n\n\n

    \n
  • China: 4,824,703<\/li>\n\n\n\n
  • India: 1,413,316<\/li>\n\n\n\n
  • Japan: 1,005,157<\/li>\n\n\n\n
  • Indonesia: 408,661<\/li>\n\n\n\n
  • South Korea: 237,701<\/li>\n\n\n\n
  • Australia: 212,332<\/li>\n\n\n\n
  • Philippines: 188,976<\/li>\n\n\n\n
  • Thailand: 183,541<\/li>\n\n\n\n
  • Vietnam: 180,480<\/li>\n<\/ul>\n\n\n\n

    These figures highlight the significant burden of cancer in the region, reinforcing the need for innovative and cost-effective treatment options facilitated through BA\/BE studies.<\/p>\n\n\n\n

    3. Mental Health<\/h4>\n\n\n\n

    Recognized as a fundamental human right, mental health is essential for the socio-economic development of all countries. As awareness and focus on mental health continue to grow, there is an increasing need for the development of new medications. This, in turn, drives the demand for BA\/BE studies to ensure that generic versions of these medications deliver the intended therapeutic effects, making mental health treatments more accessible and affordable.<\/p>\n\n\n\n

    Distribution of DALYs (disability-adjusted life years) due to mental disorders in Asia in 2019<\/h4>\n\n\n
    \n
    \"Distribution<\/figure><\/div>\n\n\n

    4. Neurology<\/h4>\n\n\n\n

    As the global population ages and awareness of neurological conditions such as Alzheimer\u2019s and Parkinson\u2019s disease increases, the demand for safe and effective treatments is rising. Japan has the highest prevalence of Alzheimer\u2019s disease worldwide, with 3,079 cases per 100,000 population, while South Korea and China have 1,119 and 924 cases per 100,000 people, respectively. In this growing therapeutic area, BA\/BE studies are essential to facilitate the introduction of generic alternatives, ensuring wider access to affordable neurological treatments.<\/p>\n\n\n\n

    Regulatory timelines in the Asia-Pacific region<\/h2>\n\n\n\n
    #<\/th>Country<\/strong><\/th>Timelines<\/strong><\/th><\/tr><\/thead>
    1<\/td>Thailand<\/a><\/strong><\/td>Clinical trial import license for approximately 30 working days, except biological cell\/gene therapy and herbal. 
    IRB\/IEC\/MREC approximately 50 days<\/td><\/tr>
    2<\/td>India<\/a><\/strong><\/td>DCGI approval Approx. 90 working days 
    Local IEC Approx 60 days<\/td><\/tr>
    3<\/td>Singapore<\/a><\/strong><\/td>Clinical trial certificate approximately 30 days
    IRB\/DSRB approximately 30 days<\/td><\/tr>
    4<\/td>Malaysia<\/a>\u00a0<\/strong><\/td>Clinical trial import license approximately 30 working days, except biological cell\/gene therapy and herbal. 
    IRB\/IEC\/MREC approximately 50 days<\/td><\/tr>
    5<\/td>South Korea<\/a>\u00a0<\/strong><\/td>Investigational new drug approximately 30 days
    IRB\/IEC approximately 30 days<\/td><\/tr>
    6<\/td>Philippines<\/a>\u00a0<\/strong><\/td>Philippine health research ethics board(PHREB) Approximately 30-60 working days 
    IRB\/IEC 30-60 working days<\/td><\/tr>
    7<\/td>Australia<\/a>\u00a0<\/strong><\/td>5-10 days via the Clinical trial notification scheme (CTN) 
    IRB\/IEC approximately 30-60 days<\/td><\/tr>
    8<\/td>Japan<\/a><\/strong><\/td>IRB\/IEC 4-8 weeks
    Regulatory Approval timeline -30 days.<\/td><\/tr>
    9<\/td>New Zealand<\/a><\/strong><\/td>Standing commission on therapeutic trial (SCOTT) less than 2 weeks
    ECs 1-4 months<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Conclusion<\/h2>\n\n\n\n

    The expanding pharmaceutical industries in the Asia-Pacific (APAC) region are actively addressing the growing demand for efficient drug development and stringent quality control measures, including bioavailability and bioequivalence (BA\/BE) studies. The APAC market offers a promising environment for BA\/BE studies due to its dynamic growth, cost-effectiveness, and regulatory advancements toward harmonization, as well as a diverse patient pool. Government initiatives are compared to enhance funding and capability development for pharmaceutical companies operating in the region.<\/p>\n\n\n\n

    Given that drug development decisions are often made on a global scale, leadership teams must stay informed about regional healthcare trends, disease prevalence, and regulatory changes. This awareness helps identify promising opportunities for BA\/BE studies within APAC.<\/p>\n\n\n\n

    Achieving the long-term goals of BA\/BE studies requires a robust framework encompassing social, environmental, governance, and regulatory pillars. These elements ensure that study outcomes are both rigorous and compliant.<\/p>\n\n\n\n

    \n\n\n\n

    Do You Have Any Questions About Conducting Your Clinical Trials in the Asia-Pacific Region?<\/h2>\n\n\n\n

    Do you have any questions about conducting your clinical trials in the Asia-Pacific region, or do you need our support with clinical trials in any specific country within this region? Please provide your requirements below, and we will connect you with our team.<\/p>\n\n\n